Generate Biomedicines plans to conduct an IPO in the United States with a maximum of $425 million.

LootboxPhobia · 2026-02-23T12:24:04+00:00

Generate Biomedicines has filed for an IPO, planning to raise up to $425 million in the United States, issuing 25 million shares at a price range of $15-$17 per share. The company focuses on using machine learning to develop protein-based therapies, involving immunology, oncology, and infectious diseases.

LootboxPhobia

2026-02-23 12:24:04

Abstract generation in progress

Investing.com – Generate Biomedicines filed for an initial public offering on Monday, aiming to raise up to $425 million in the United States.

This biotech company plans to issue 25 million shares at a price range of $15 to $17 per share. The company intends to list on Nasdaq under the ticker symbol GENB.

Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor will serve as underwriters for the offering.

Generate Biomedicines is a drug development company that uses machine learning to design and optimize proteins for therapeutic applications. The company focuses on immunology, oncology, and infectious diseases.

Headquartered in Cambridge, Massachusetts, the company was founded in 2018.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.